Through our social mandate, APL has built up a very strong ability to adapt medicines to individual needs, and this in turn has made us attractive to the research sector. One of the companies that has discovered the advantages of APL is the British company Modepharma – a company that distributes clinical trial materials to non-commercial studies in the United Kingdom. Modepharma and APL have collaborated since a successful meeting at CPhI (Convention on Pharmaceutical Ingredients) in Madrid in 2009.
Our joint projects have varied in size, and the most recent has also been the largest to date. This study aimed to evaluate a tried and tested therapy, and for three years APL has manufactured and delivered 120 000 pre-filled syringes with active substance and placebo. The first batch of 3 000 syringes was sent in August 2014. Since then, we have filled, analysed, labelled, packaged, released and delivered fifteen batches, or 120 000 syringes. We have also carried out three stability studies, extended the shelf life from six to twelve months, increased the batch size from 1 500 to 5 000 syringes, validated microbiological methods and reduced the price of the input materials by 30 percent.
Oliver Gupta, MD of Modepharma, chose to collaborate with APL in part due to our flexible attitude and ability to adapt most factors, from batch size and packaging, to shelf life and delivery times.
APL is flexible, pragmatic and very nice to work with,” says Oliver Gupta. “It is clear that they collaborate effectively and well, as they always come back with very thought-through answers to our questions. Everything is high quality, and they are also very transparent – with both good and bad news, which builds confidence. And they answer quickly. I would definitely recommend APL as a supplier of clinical trial material, because they are a joy to work with.
The project with the pre-filled syringes is expected to continue and be concluded during 2017.
If you have any questions about clinical trial material, please contact email@example.com.